Gilead exercises options to three arcus biosciences clinical-stage programs and adds research collaboration

Foster city, calif. & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) and arcus biosciences, inc. (nyse: rcus) today announced that gilead has exercised its options to three programs in arcus's clinical-stage portfolio, including both anti-tigit molecules, domvanalimab and ab308, as well as etrumadenant and quemliclustat. the companies also added a research collaboration as described below. today's transaction is subject to applicable antitrust clearance under the hart-sc
RCUS Ratings Summary
RCUS Quant Ranking